argenx (ARGX) investor relations material

Executive summary

• Q3 product net sales were $1.721B, up 54% YoY and 13% QoQ; profit for the period was $506M versus $344M in Q3 2025.

• Vision 2030 targets 50,000 patients, 10 labeled indications and five pipeline candidates in registrational development.

Financial highlights

• Q3 total operating income was $1.751B versus $1.151B; 9M 2026 total operating income was $4.605B versus $2.926B.

• Q3 operating profit was $486M versus $346M; profit before tax was $538M versus $386M, and profit for the period was $506M versus $344M.

• Q3 operating expenses were $1.266B, including R&D of $503M and SG&A of $598M; combined R&D and SG&A were up 22% QoQ, or 5% excluding $150M in Forte costs.

• Regional product net sales were U.S. $1.471B, Japan $81M, rest of world $158M and $11M supplied to Zai Lab in China.

• 9M product net sales were $4.534B versus $2.866B; 9M operating profit was $1.372B versus $686M and profit was $1.344B versus $759M.

Outlook and guidance

• FY 2026 combined R&D and SG&A guidance is ~$4B, up 45% YoY; about half of the increase versus prior Street expectations relates to Forte and FB-102 investment.

• Up to five potential efgartigimod launches are targeted for 2027, subject to clinical results and regulatory review and approval; the autoinjector potential launch is in H2 2027.

• Pediatric gMG has a February 18, 2027 PDUFA date; ocular MG sBLA was submitted, and an IMNM sBLA is on track for year-end 2026.

• Empasiprubart Phase 3 MMN topline results are expected in December 2026; CIDP Phase 3 results are anticipated in H2 2027.

• ADVANCE-NEXT Phase 3 ITP topline results are expected in H1 2027; 2027 expense growth was suggested directionally at about half the 2026 increase, with fuller guidance expected at JPMorgan.